我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

阿托伐他汀钙对原发性高胆固醇血症患者血管内皮细胞依赖性舒张功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第6期
页码:
494-496
栏目:
临床研究
出版日期:
2002-11-01

文章信息/Info

Title:
Tne effect of cholesterol-lowering therapy with atorvastatin on endothe-lium-dependent relaxing function in patients with hypercholesterolemia
作者:
吴奇志1 翁南星1 兰启防1 林 涛2
1.厦门市湖里医院心内科,福建厦门 361006;2.福建省老年病医院心内科,福建福州 350003
Author(s):
WU Qi-zhi1 WENG Nan-xing1 LAN Qi-fang1 LIN Tao2
1.Department of Cardiology, Huli Hospital, Xiamen, Fujian 361006, China
关键词:
阿托伐他汀钙高胆固醇血症内皮超声检查多普勒
Keywords:
atorvastatinhypercholesterolemiaendothelimultrasonographyDoppler
分类号:
R543.5, R972
DOI:
-
文献标识码:
A
摘要:
目的 研究阿托伐他汀钙对原发性高胆固醇血症(HTC)患者血管内皮细胞依赖性舒张功能(FMD)的影响。方法 采用高分辨率超声技术,对30例HTC患者用阿托伐他汀钙治疗前后和30例血浆胆固醇(TC)水平正常的对照(NC)组的血管FMD进行检测。结果 HTC组肱动脉FMD较NC组明显减弱(3.4%±2.6%vs13.8%±3.8%,P<0.01),而两组对硝酸甘油反应的内皮非依赖性舒张功能(NMD)无显著性差异(P>0.05)。30例HTC患者服用阿托伐他汀钙10 mg治疗12周后,TC从6.3±0.6 mmol/L降至5.0±0.5 mmol/L,甘油三酯(TG)从1.8±0.4mmol/L降至1.5±0.6 mmol/L,LDL-C从4.2±0.5 mmol/L降至3.0±0.6 mmol/L,同时FMD较治疗前显著改善(11.6%±3.3%vs3.4%±2.6%,P<0.01),而治疗前后肱动脉NMD无显著性改变(P>0.05)。结论 HTC患者存在FMD障碍,经阿托伐他汀钙降胆固醇治疗后,受损的血管FMD有明显改善。
Abstract:
AIM To investigate the effect of cholesterol-lowering therapy with atorvastatin on endothelium-dependent relaxing function in patients with hypercholesterolemia(HTC).METHODS With high-resolution ultrasound,we measured endothelium-dependent relaxing-function in 60 subjects:30 with normal blood cholesterol and the others with established primary HTC.RESULTS In patients with primary HTC,flow-mediated dilatation in arteries was markedly reduced comparied with the control group(3.4%±2.6%vs13.8%±3.8%,P<0.01),However,there was no significant difference in the response to nitroglycerin between the two groups(P>0.05). The 30 HTC patients were studied before and after cholesterol-lowering therapy with atorvastatin for 12 weeks,during which serum TC lowered from 6.3±0.6 mmol/L to 5.0±0.5 mmol/L(P< 0.01),TG lowered from 1.8±0.4 mmol/L to 1.5±0.6 mmol/L(P<0.05), and LDL-C?low-ered from 4.2±0.5 mmol/L to 3.0±0.6 mmol/L(P<0.01). Flow-mediated vasodilations were greater after the atorvastatin therapy than before it (11.6±3.3%vs3.4±2.6%,P<0.01).There was no significant change in vasodilations response to nitroglycerin after the cholesterol-lowering therapy(P>0.05).CONCLUSION Endothelium-dependent vasoldilation was impaired in patients with primary HTC,and cholesterol-lowering therapy with atorvastatin may the improve impaired endothelium-dependent vasodilation.

参考文献/References

[1] Gelermajer DS,Sorensen KE,Bull C,et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk of factors and their interaction[J].J Am Coll Cardiol,1994,24:1468-1474.

[2] Doi H,Kugiyama K,Ohgushi M,et al. Remnants of chylomicron and very low density lipoprotein impair endothelium-depended vasorelaxation[J].Atherosclerosis,1998,137:341-349.

[3]李 江,赵水平,李向平,等.辛伐他汀降脂治疗对血管内皮依赖性舒张功能的影响[J].中华心血管病杂志,1998,24:278-281.

[4]刘群锋,马 虹,周少春,等.高脂饮食兔血管内皮功能障碍的早期变化[J].心脏杂志,2001,13(5):352.

[5] Treasure CB,Klein L, Weinteraub WS,et al. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease[J].N Engl J Med,1995,332:481-487.

[6] Voger RA,Corretti MC,Plotmick GD,et al. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men[J].Am J Cardiol,1996,77:37-40.

备注/Memo

备注/Memo:
收稿日期:2001-12-10.
更新日期/Last Update: 2002-11-01